Junichiro Watanabe (J Watanabe)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 18

Top Topics

Locally Advanced

Endoplasmic Reticulum

Estrogen Receptor

Metastatic Breast Cancer

Top Venues

Breast cancer research and treatment

Japanese journal of clinical oncology

Scientific reports

This page only lists publications with an associated author ORCID identifier.

Publications

Toshitaka Uomori, Yoshiya Horimoto, Yuko Ueki, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Junichiro Watanabe, Naoto Shikama
Efficacy of radiation therapy in Japanese patients with positive margins after breast-conserving surgery. Japanese journal of clinical oncology 54 (5) (2024)
Toshitaka Uomori, Yoshiya Horimoto, Yuko Ueki, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Junichiro Watanabe, Naoto Shikama
Efficacy of radiation therapy in Japanese patients with positive margins after breast-conserving surgery. Japanese journal of clinical oncology 54 (5) (2024)
Toshitaka Uomori, Yoshiya Horimoto, Yuko Ueki, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Junichiro Watanabe, Naoto Shikama
Efficacy of radiation therapy in Japanese patients with positive margins after breast-conserving surgery. Japanese journal of clinical oncology (2024)
Toshitaka Uomori, Yoshiya Horimoto, Yuko Ueki, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Junichiro Watanabe, Naoto Shikama
Efficacy of radiation therapy in Japanese patients with positive margins after breast-conserving surgery. Japanese journal of clinical oncology 54 (5) (2024)
Yumiko Ishizuka, Yoshiya Horimoto, Hidetaka Eguchi, Fumi Murakami, Katsuya Nakai, Hiroko Onagi, Takuo Hayashi, Takashi Ishikawa, Masami Arai, Junichiro Watanabe
BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer. Breast cancer research and treatment (2023)
Ryoko Semba, Yoshiya Horimoto, Madoka Sakata-Matsuzawa, Yumiko Ishizuka, Kaori Denda-Nagai, Haruhiko Fujihira, Miki Noji, Hiroko Onagi, Miyu Ichida, Hiroyoshi Miura, Junichiro Watanabe, Mitsue Saito, Tsuyoshi Saito, Atsushi Arakawa, Tatsuro Irimura
Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancer. Scientific reports 13 (1) (2023)
Ryoko Semba, Yoshiya Horimoto, Madoka Sakata-Matsuzawa, Yumiko Ishizuka, Kaori Denda-Nagai, Haruhiko Fujihira, Miki Noji, Hiroko Onagi, Miyu Ichida, Hiroyoshi Miura, Junichiro Watanabe, Mitsue Saito, Tsuyoshi Saito, Atsushi Arakawa, Tatsuro Irimura
Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancer. Scientific reports 13 (1) (2023)
Akihiko Shimomura, Toshimi Takano, Shunji Takahashi, Yasuaki Sagara, Junichiro Watanabe, Eriko Tokunaga, Tetsu Shinkai, Takahiro Kamio, Kunika Kikumori, Emi Kamiyama, Yoshihiko Fujisaki, Dan Saotome, Toshinari Yamashita
Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer. Clinical pharmacology and therapeutics (2022)
Hikari Jimbo, Yoshiya Horimoto, Yumiko Ishizuka, Noriko Nogami, Ayana Shikanai, Mitsue Saito, Junichiro Watanabe
Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer. Breast cancer research and treatment 196 (2) (2022)
Shogo Nakamoto, Junichiro Watanabe, Shoichiro Ohtani, Satoshi Morita, Masahiko Ikeda
Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study. BMC cancer 22 (1) (2022)
Junichiro Watanabe, Koichi Mitsuya, Shogo Nakamoto, Hideyuki Harada, Shoichi Deguchi, Nakamasa Hayashi, Yoko Nakasu
Leptomeningeal Metastasis in ER + HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period. Breast cancer research and treatment 189 (1) (2021)
Shogo Nakamoto, Junichiro Watanabe, Shoichiro Ohtani, Satoshi Morita, Masahiko Ikeda
Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study. Scientific reports 11 (1) (2021)
Shunji Takahashi, Masato Karayama, Masato Takahashi, Junichiro Watanabe, Hironobu Minami, Noboru Yamamoto, Ichiro Kinoshita, Chia-Chi Lin, Young-Hyuck Im, Issei Achiwa, Emi Kamiyama, Yasuyuki Okuda, Caleb Lee, Yung-Jue Bang
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (21) (2021)
Taiyo Leopoldo Harada, Takayoshi Uematsu, Kazuaki Nakashima, Takanori Kawabata, Seiichirou Nishimura, Kaoru Takahashi, Yukiko Tadokoro, Tomomi Hayashi, Kazuyo Tsuchiya, Junichiro Watanabe, Takashi Sugino
Evaluation of Breast Edema Findings at T2-weighted Breast MRI Is Useful for Diagnosing Occult Inflammatory Breast Cancer and Can Predict Prognosis after Neoadjuvant Chemotherapy. Radiology 299 (1) (2021)
Junichiro Watanabe
Reply to letters to the editor: Discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer. Breast cancer research and treatment 182 (2) (2020)
Junichiro Watanabe, M Saito, Yoshiya Horimoto, S Nakamoto
A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. Breast cancer research and treatment 181 (1) (2020)
Junichiro Watanabe, T Hayashi, Y Tadokoro, S Nishimura, K Takahashi
Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. Breast cancer research and treatment 166 (3) (2017)
Satomi Matsuo, Junichiro Watanabe, Koichi Mitsuya, Nakamasa Hayashi, Yoko Nakasu, Mitsuhiro Hayashi
Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. Breast cancer research and treatment 162 (1) (2017)